Catalent (CTLT)
(Delayed Data from NYSE)
$56.51 USD
+0.31 (0.55%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $56.58 +0.07 (0.12%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Company Summary
Somerset, NJ-based Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Catalent operates through two arms following the change in its organizational structure. This includes a shift from four reporting segments to two — newly formed Pharma and Consumer Health (PCH) segment (consolidating the prior Softgel & Oral Technologies, Oral & Specialty Delivery and Clinical Supply Services segments) and Biologics. Each represents roughly half of Catalent’s total revenue.
...
Company Summary
Somerset, NJ-based Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Catalent operates through two arms following the change in its organizational structure. This includes a shift from four reporting segments to two — newly formed Pharma and Consumer Health (PCH) segment (consolidating the prior Softgel & Oral Technologies, Oral & Specialty Delivery and Clinical Supply Services segments) and Biologics. Each represents roughly half of Catalent’s total revenue.
Biologics (46.4% of aggregate revenues in FY 2023, down 21% at constant exchange rate or CER from FY 2022): The segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing; formulation, development, and manufacturing of parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. Further, the growing biologics offering includes cell-line development based on Catalent’s advanced and patented GPEx technology and the GPEx Boost.
PCH (53.6%, up 4%): The PCH segment encompasses the offerings of three of the company's prior reportable segments — Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services — and comprises Catalent’s capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
General Information
Catalent, Inc
14 SCHOOLHOUSE ROAD
SOMERSET, NJ 08873
Phone: 732-537-6200
Fax: 732-537-6480
Email: investors@catalent.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | June |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 9/3/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.46 |
Current Year EPS Consensus Estimate | 0.13 |
Estimated Long-Term EPS Growth Rate | 29.20 |
Exp Earnings Date | 9/3/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 56.20 |
52 Week High | 60.20 |
52 Week Low | 31.80 |
Beta | 1.16 |
20 Day Moving Average | 1,523,269.38 |
Target Price Consensus | 60.07 |
4 Week | 1.87 |
12 Week | -0.89 |
YTD | 25.77 |
4 Week | -1.49 |
12 Week | -7.63 |
YTD | 8.35 |
Shares Outstanding (millions) | 180.98 |
Market Capitalization (millions) | 10,227.17 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 48.13 |
Trailing 12 Months | NA |
PEG Ratio | 1.65 |
vs. Previous Year | -25.00% |
vs. Previous Quarter | 54.55% |
vs. Previous Year | 3.57% |
vs. Previous Quarter | 4.07% |
Price/Book | 2.83 |
Price/Cash Flow | 17.42 |
Price / Sales | 2.46 |
6/30/24 | NA |
3/31/24 | -2.73 |
12/31/23 | -2.43 |
6/30/24 | NA |
3/31/24 | -1.06 |
12/31/23 | -0.98 |
6/30/24 | NA |
3/31/24 | 2.51 |
12/31/23 | 2.48 |
6/30/24 | NA |
3/31/24 | 1.77 |
12/31/23 | 1.73 |
6/30/24 | NA |
3/31/24 | -2.59 |
12/31/23 | -2.48 |
6/30/24 | NA |
3/31/24 | -26.61 |
12/31/23 | -29.91 |
6/30/24 | NA |
3/31/24 | -29.89 |
12/31/23 | -34.91 |
6/30/24 | NA |
3/31/24 | 19.95 |
12/31/23 | 20.41 |
6/30/24 | NA |
3/31/24 | 4.34 |
12/31/23 | 4.35 |
6/30/24 | NA |
3/31/24 | 1.37 |
12/31/23 | 1.34 |
6/30/24 | NA |
3/31/24 | 57.74 |
12/31/23 | 57.36 |